Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Combination with Radiotherapy for Adjuvant Therapy in Upper Tract Urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results